Second Department of Orthopedics, Beijing Daxing District People's Hospital, Beijing, China.
Department of Orthopedics, Aerospace Central Hospital, Beijing, China.
Cancer Rep (Hoboken). 2024 Aug;7(8):e2159. doi: 10.1002/cnr2.2159.
BACKGROUND: Ring finger protein 135 (RNF135) is an E3 ubiquitin ligase that has been implicated in the tumorigenesis of multiple human malignancies. However, whether RNF135 plays a role in the development of human osteosarcoma (OS) remains unknown. METHODS: RNF135 expression in 20 human OS and 20 human osteochondroma specimens were evaluated by means of immunohistochemistry staining. The effects of shRNA-mediated RNF135 knockdown on human OS cell growth and apoptosis were evaluated through a panel of in vitro studies on cell proliferation, colony formation, exposure of phosphatidylserine on the cell surface, and caspase 3/7 activation. The protein levels of PI3K, AKT, and p-AKT were determined by western blot analysis. RESULTS: We detected significantly higher RNF135 levels in human OS tissues than human osteochondroma tissues. In in vitro studies, shRNA-mediated RNF135 knockdown in human OS cells inhibited proliferation and induced apoptosis. In addition, RNF135 knockdown reduced PI3K and p-AKT protein levels and activated caspase 3 and 7. CONCLUSIONS: These results supported that RNF135 contributes to human OS development through PI3K/AKT-dependent mechanisms. Targeting RNF135 may provide a new therapeutic approach for treating this human malignancy.
背景:环指蛋白 135(RNF135)是一种 E3 泛素连接酶,与多种人类恶性肿瘤的发生有关。然而,RNF135 是否在人类骨肉瘤(OS)的发展中起作用尚不清楚。
方法:通过免疫组织化学染色评估 20 个人类 OS 和 20 个人类骨软骨瘤标本中的 RNF135 表达。通过体外细胞增殖、集落形成、细胞膜上磷脂酰丝氨酸暴露和 caspase 3/7 激活研究,评估 shRNA 介导的 RNF135 敲低对人骨肉瘤细胞生长和凋亡的影响。通过 Western blot 分析测定 PI3K、AKT 和 p-AKT 的蛋白水平。
结果:我们在人骨肉瘤组织中检测到明显高于人骨软骨瘤组织的 RNF135 水平。在体外研究中,shRNA 介导的人骨肉瘤细胞中 RNF135 敲低抑制增殖并诱导细胞凋亡。此外,RNF135 敲低降低了 PI3K 和 p-AKT 蛋白水平,并激活了 caspase 3 和 7。
结论:这些结果表明,RNF135 通过 PI3K/AKT 依赖性机制促进人类 OS 的发展。针对 RNF135 可能为治疗这种人类恶性肿瘤提供一种新的治疗方法。
Cancer Rep (Hoboken). 2024-8
Cell Physiol Biochem. 2018
Eur Rev Med Pharmacol Sci. 2018-9
Curr Mol Pharmacol. 2024
Curr Osteoporos Rep. 2023-8
Front Oncol. 2023-2-10
Exp Hematol Oncol. 2023-1-9
Front Oncol. 2022-12-1
Annu Rev Biochem. 2021-6-20